GlaxoSmithKline and Pfizer have entered into an agreement to create a new company focused solely on research, development and commercialization of HIV drugs. The focus of the new business will be to invest in R&D of innovative HIV treatments and formulations that improve adherence and overcome resistance to the virus. With their combined portfolios, the new HIV business will hold a 19% share of the market. GSK will initially hold an 85% equity interest in the new company and Pfizer will hold...